Breaking News Instant updates and real-time market news.

GE

General Electric

$7.27

0.13 (1.82%)

, GSK

GlaxoSmithKline

$37.09

0.02 (0.05%)

09:14
12/19/18
12/19
09:14
12/19/18
09:14

Fly Intel: Pre-market Movers

HIGHER: General Electric (GE), up 4% after report that it confidentially filed for an initial public offering of its healthcare unit... GlaxoSmithKlein (GSK), up 6% after announcing with Pfizer (PFE) that they have entered into an agreement to combine their consumer healthcare units into one joint venture. UP AFTER EARNINGS: General Mills (GIS), up 5%... Winnebago (WGO), up 9%... Paychex (PAYX), up 2%... Jabil (JBL), up 10%. DOWN AFTER EARNINGS: FedEx (FDX), down 7%... Lam Research (LRCX), down 3%... Micron (MU), down 7%. LOWER: Facebook (FB), down nearly 2% after NY Times reports Facebook gave tech giants greater access to user data... Surface Oncology (SURF), down 19% after announcing a reduction of investment in and scope of its SRF231 program.

GE

General Electric

$7.27

0.13 (1.82%)

GSK

GlaxoSmithKline

$37.09

0.02 (0.05%)

PFE

Pfizer

$42.39

-0.72 (-1.67%)

FDX

FedEx

$185.01

2.81 (1.54%)

MU

Micron

$34.12

0.23 (0.68%)

FB

Facebook

$143.64

3.33 (2.37%)

GIS

General Mills

$36.70

-0.03 (-0.08%)

JBL

Jabil

$22.21

0.65 (3.01%)

LRCX

Lam Research

$138.01

2.39 (1.76%)

SURF

Surface Oncology

$7.35

-0.44 (-5.65%)

WGO

Winnebago

$19.96

-0.73 (-3.53%)

PAYX

Paychex

$64.32

-0.63 (-0.97%)

  • 19

    Dec

  • 19

    Dec

  • 19

    Dec

  • 05

    Jan

  • 08

    Jan

  • 29

    Jan

GE General Electric
$7.27

0.13 (1.82%)

12/13/18
12/13/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. General Electric (GE) upgraded to Neutral from Underweight at JPMorgan with analyst Stephen Tusa saying he's less negative on the shares with the abating of "known unknowns." 2. Five Below (FIVE) upgraded to Buy from Neutral at Goldman Sachs with analyst Christopher Prykull saying the 18% decline in the stock price over the past month is "disconnected" from the company's robust fundamentals and believes that there is a 20% upside to his price target. 3. Tractor Supply (TSCO) upgraded to Buy from Hold at Deutsche Bank with analyst Michael Baker citing valuation. 4. Procter & Gamble (PG) upgraded to Buy from Neutral at BofA/Merrill with analyst Olivia Tong saying after meetings with CFO Jon Moeller, she believes that the company's early momentum in Q1 of FY19 can be sustained. 5. Dycom (DY) upgraded to Buy from Hold at Craig-Hallum with analyst Christian Schwab saying he believes shares at current levels have become attractive again. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/13/18
JPMS
12/13/18
UPGRADE
Target $6
JPMS
Neutral
General Electric upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Stephen Tusa upgraded General Electric to Neutral from Underweight with an unchanged price target of $6. The stock closed yesterday down 5c to $6.71. The analyst says he's less negative on the shares with the abating of "known unknowns." Tusa, however, increasingly assumes a "material equity raise could be necessary." While such an event would create near-term downside in GE shares, there "could be support at a lower level, and likely a benefit of the doubt for new management with a higher multiple on lower earnings" and free cash flow, Tusa tells investors in a research note partially titled "Gonna Walk Before They Make Me Run." The analyst sees a more balanced risk/reward following the recent selloff in General Electric shares.
12/10/18
SUSQ
12/10/18
NO CHANGE
Target $24
SUSQ
Neutral
GE stake in Baker Hughes remains an overhang, says Susquehanna
Susquehanna analyst Charles Minervino said Baker Hughes (BHGE) management expressed optimism about its end market diversification, global oilfield footprint and robust backlog in recent meetings and noted the company has not made any changes to its outlook assumptions disclosed on the Q3 call. While he thinks Baker Hughes has done "a very admirable job" of managing the new organization since the GE (GE) merger, Minervino keeps a Neutral rating on the stock given the lingering GE 50.4% ownership overhang. After lowering his 2019 EPS estimate to $1.29 from $1.39 to account for model changes and the recent move in crude prices, Minervino lowered his price target on Baker Hughes shares to $24 from $31.
12/19/18
VERT
12/19/18
UPGRADE
VERT
Buy
General Electric upgraded to Buy from Hold at Vertical Research
Vertical Research analyst Jeffrey Sprague upgraded General Electric to Buy from Hold with an $11 price target.
GSK GlaxoSmithKline
$37.09

0.02 (0.05%)

12/13/18
RHCO
12/13/18
INITIATION
RHCO
Hold
GlaxoSmithKline initiated with a Hold at SunTrust
SunTrust analyst John Boris initiated GlaxoSmithKline with a Hold rating and $38 price target, expecting the company's respiratory franchise to stagnate with Advair generic competition expected in the near-term.
12/14/18
LEER
12/14/18
NO CHANGE
LEER
Outperform
Tesaro proxy documents point to interest in PARP economics, says Leerink
Leerink analyst Andrew Berens noted that GlaxoSmithKline (GSK) and Tesaro (TSRO) disclosed background details for their deal agreement in a filing this morning. The documents show several parties were interested in a strategic transaction with Tesaro at various points over the last year, though the strategic interest appears to have been driven by Glaxo and one additional company, identified as "Party A", Berens said. It is not clear why the six other contacted parties were not interested in pursuing a strategic transaction, but he thinks Party A's co-promote proposal and the initial interest of other potential acquirers indicates strategic interest in the economics surrounding a PARP. Berens, who continues to see Clovis (CLVS) being well-positioned as the remaining stand-alone PARP-focused company, keeps an Outperform rating on Clovis and Market Perform rating on Tesaro.
12/14/18
12/14/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with an Outperform at Wedbush and a Hold at Deutsche Bank. 2. New York Times (NYT) initiated with an Outperform at Evercore ISI. 3. Ford (F) and General Motors (GM) were initiated with a Buy at Deutsche Bank, while Autoliv (ALV) was initiated with a Sell. 4. AstraZeneca (AZN) initiated with a Buy at SunTrust while GlaxoSmithKline (GSK) was initiated with a Hold. 5. DaVita (DVA) initiated with an Overweight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/11/18
GABE
12/11/18
NO CHANGE
GABE
Buy
Gabelli sees Clovis as likely takeout target, top biotech pick in 2019
Gabelli analyst Jing He highlights Clovis (CLVS) as his top biotech pick in 2019. With the Tesaro (TSRO) acquisition by GlaxoSmithKline (GSK), Clovis will become the only standalone PARP, which the analyst believes makes it the most likely takeout target in 2019. He continues to believe Bristol-Myers (BMY), Sanofi (SNY) and Roche (RHHBY) to be the most interested buyers. The analyst reiterates a Buy rating on Clovis' shares.
PFE Pfizer
$42.39

-0.72 (-1.67%)

11/19/18
CANT
11/19/18
NO CHANGE
Target $53
CANT
Overweight
Pfizer's oncology assets are underappreciated, says Cantor Fitzgerald
Pfizer's oncology assets will make up 13% of its total 2018 sales and they will accelerate the company's sales growth for the foreseeable future, but these drugs are underappreciated, Cantor Fitzgerald analyst Louise Chen tells investors in a research note. Pfizer has said that through 2022 it expects 15 potential blockbusters to be launched, and oncology drugs are represented in these opportunities, the analyst points out. She sees upside to consensus estimates and keeps an Overweight rating on Pfizer with a $53 price target.
11/27/18
LEER
11/27/18
INITIATION
LEER
Leerink initiates select Genetic Medicine names on increasing regulatory clarity
Leerink analyst Mani Foroohar initiated select Genetic Medicine stocks, stating that the field is "is rich with companies developing drugs" to treat rare diseases and that he is increasingly more bullish on "innovation velocity and increasing regulatory clarity in the sector. Based on his "balanced view of pricing dynamics", the analyst issues an Outperform rating on Wave Life Sciences (WVE), Rocket Pharmaceuticals (RCKT), Intellia Therapeutics (NTLA), Eidos Therapeutics (EIDX), Dicerna (DRNA) and Bluebird Bio (BLUE). The analyst likes Wave Life Sciences as a pure play on Oligotherapeutics and its stereopure chemistry platform as a differentiated approach to oligo drug design. Foroohar is positive on Rocket Pharma's lead assets in gene therapies for Fanconi Anemia and Leukocyte Adhesion Deficiency-I "which will likely be the company's first potential approved product." The analyst is positive on Intellia Therapeutics' "robust balance sheet to support development, trading at a material discount to closest comps peers". For Eidos, the analyst cites the prospects of its drug candidate for TTR amyloidosis currently in a placebo-controlled Phase 2 study that may offer a competitive profile relative to Pfizer's (PFE) tafamidis. For Dicerna, Foroohar notes that its DCR-PHXC "is an RNAi therapeutic that targets lactate dehydrogenase A for the treatment of all subtypes of Primary Hyperoxaluria vs. competitor Alnylam's (ALNY) lumasiran, which only treats PH Type 1. For Bluebird Bio, the analyst is positive on its position as a "leader in ex vivo gene therapy, with four programs with visibility towards near-term regulatory approval". Foroohar initiates Avrobio (AVRO), Alnylam (ALNY), and Ionis Pharmaceuticals (IONS) with Market Perform rating based on competitive launches for their products along with "mixed" early signs of their results. The analyst also rates Regenxbio (RGNX) at underperform, saying that its "current valuation more than accounts for robust royalty streams from sales in spinal muscular atrophy" and other partnered assets.
12/11/18
JPMS
12/11/18
DOWNGRADE
Target $46
JPMS
Neutral
Pfizer downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Christopher Schott downgraded Pfizer to Neutral with an unchanged price target of $46. The shares closed yesterday up 48c to $44.40. The analyst cites valuation for his move to the sidelines after a "strong" 2018 which has to the stock up over 20% year-to-date. Further, he believes Pfizer's product pipeline needs to expand following the patent expiration of Lyrica in 2019.
12/11/18
12/11/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pfizer (PFE) downgraded to Neutral from Overweight at JPMorgan with analyst Christopher Schott citing valuation. 2. Splunk (SPLK) resumed with a Neutral from Buy at Guggenheim with analyst Imtiaz Koujalgi saying while the company's fundamentals are strong, he's "looking for more clarity." 3. CalAmp (CAMP) downgraded to Outperform from Strong Buy at First Analysis and to Market Perform from Outperform at Northland. 4. Acorda Therapeutics (ACOR) downgraded to Sell from Neutral at Goldman Sachs with analyst Salveen Richter saying the commercial outlook for Inbrija appears limited. 5. Versum Materials (VSM) downgraded to Sell from Neutral at Goldman Sachs with analyst Toshiya Hari saying while he remains constructive on the Semiconductor Materials sub-sector broadly, he believes the market is underestimating the extent to which weaker semiconductor capital expenditures could negatively impact the Delivery Systems and Services segment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
FDX FedEx
$185.01

2.81 (1.54%)

12/19/18
MSCO
12/19/18
NO CHANGE
MSCO
Equal Weight
FedEx guidance cut expected, magnitude worse than expected, says Morgan Stanley
Morgan Stanley analyst Ravi Shanker noted that he had previewed a miss and guidance cut coming from FedEx, but the magnitude of the reduction was much bigger than he expected. He points out that his $16.61 EPS estimate for FY19 was 3.5% below the low end of the previous range, but is now slightly above the high end of the company's new range. Shanker recognizes that global growth has slowed, but he was "very surprised" by the magnitude of this headwind, adding that he believes global growth concerns are likely to get worse before they get better next year. The analyst, whose model and price target are under review, keeps an Equal Weight rating on FedEx shares.
12/19/18
COWN
12/19/18
NO CHANGE
Target $242
COWN
Outperform
FedEx price target lowered to $242 from $280 at Cowen
Cowen analyst Helane Becker lowered her price target on FedEx to $242 from $280 and she expects the shares to remain under pressure following Q2 results. She noted the company cited global macro concerns, including a weakening in Europe and China, and is taking steps by reducing capacity, cutting costs, and raising rates. Becker maintained her Outperform rating on FedEx shares.
12/19/18
OPCO
12/19/18
NO CHANGE
Target $234
OPCO
Outperform
FedEx price target lowered to $234 from $288 at Oppenheimer
Oppenheimer analyst Scott Schneeberger lowered his price target for FedEx to $234 from $288 following quarterly results. The analyst notes that peak appears "strong," but adds that guidance was reduced largely on slowing global trade outlook. He reiterates an Outperform rating on the shares.
12/19/18
BMOC
12/19/18
NO CHANGE
Target $245
BMOC
Outperform
FedEx price target lowered to $245 from $270 at BMO Capital
BMO Capital analyst Fadi Chamoun lowered his price target on FedEx to $245 after its Q2 earnings and guidance cut yesterday evening, saying that the "impact of slowing global growth on Express results" is "sharper than anticipated". The analyst contends that a "serious" recovery in FedEx stock price is unlikely in the near term following a reset in earnings expectations and the growing macro uncertainty. Chamoun keeps his Outperform rating on the shares longer term however, noting that valuation is "compelling at current levels" and believes that the investments FedEx made in its Ground business are "starting to pay off."
MU Micron
$34.12

0.23 (0.68%)

12/19/18
LBOW
12/19/18
NO CHANGE
LBOW
Neutral
Micron 'getting close' to a bottom, says Longbow
Longbow analyst Joe Wittine noted that Micron guided February quarter results materially lower, as expected, citing broadly weak end markets, a transition year ahead for SSDs, and falling bit prices for both DRAM and NAND. In a note entitled "Getting Close to the Bottom," Wittine said that the company's estimates for 2019 DRAM and NAND bit growth seem to imply "relatively healthy" August and November quarter bit growth forecasts. He maintains a Neutral rating on Micron shares.
12/19/18
KEYB
12/19/18
NO CHANGE
Target $45
KEYB
Overweight
Micron price target lowered to $45 from $61 at KeyBanc
KeyBanc analyst Weston Twigg lowered his price target for Micron to $45 from $61 after the company reported results in line with its Q1 preannouncement, but offered Q2 guidance well below consensus as customers continue to draw down inventory in the face of softening demand and growing uncertainty into 1H19. Still, the analyst thinks Micron is performing relatively well, with margins likely to hold up better than past cycles. Twigg reiterates an Overweight rating on the shares as he believes in strong, long-term demand drivers and solid execution throughout cycles
12/19/18
RBCM
12/19/18
DOWNGRADE
Target $40
RBCM
Sector Perform
Micron downgraded to Sector Perform at RBC Capital on inventory, demand risks
As reported earlier, RBC Capital analyst Amit Daryanani downgraded Micron to Sector Perform from Outperform and lowered his price target to $40 from $59 after its disappointing Q2 outlook. The analyst cites the company's inventory risk, as the "ongoing" industry downturn has increased its inventories by 22% "and heading higher" in the February quarter, warning that memory also tends to be a "depreciating asset" as the industry correction gets more "severe". Daryanani is also concerned with "Demand risk" for Micron, with real possibility that the issue requires further reduction in capacity and/or lower pricing in mid-2019. Additionally, the analyst cites competitive risk given the lack of clarity about its peers' intentions to reduce capacity and an upside inflection in Micron's operating expenses, which could pressure earnings further in Q3.
12/19/18
MSCO
12/19/18
NO CHANGE
Target $33
MSCO
Equal Weight
Micron price target lowered to $33 from $48 at Morgan Stanley
Morgan Stanley analyst Joseph Moore said Micron's climbing inventory levels validate his previously expressed undershipment concerns and that inventory has to be cleared out for supply and demand to come into balance. The company's capital spending cuts will help, but fixing the situation will take time, contends Moore, who lowered his price target on Micron shares to $33 from $48 following the company's Q1 report. He maintains an Equal Weight rating on Micron.
FB Facebook
$143.64

3.33 (2.37%)

12/06/18
12/06/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Facebook (FB) downgraded to Hold from Buy at Stifel with analyst Scott Devitt saying Facebook has made too many enemies, including politicians, regulators, technology leaders, consumers, and employees, to not experience "long-term negative ramifications on its business." 2. Conatus (CNAT) downgraded to Hold from Buy at Stifel with analyst Stephen Willey saying the Encore-PH trial missed its pre-specified primary endpoint but post-hoc analyses demonstrated a trend towards statistically significant/emricasan-mediated improvements in patients with compensated cirrhosis and elevated baseline hepatic venous pressure gradient values. 3. BHP Billiton (BHP) downgraded to Neutral from Overweight at JPMorgan with analyst Lyndon Fagan saying the stock has outperformed Rio Tinto (RIO) by 10% year-to-date, and is now trading "within range of our valuation." 4. Toll Brothers (TOL) downgraded to Sector Perform from Outperform at RBC Capital with analyst Michael Dahl citing a "sharper than expected weakness in orders and likelihood of further near-term declines," with softer margin assumptions attributed to a weaker outlook for orders. 5. Bluebird Bio (BLUE) downgraded to Neutral from Overweight at Piper Jaffray with analyst Tyler Van Buren saying the company is "incredibly innovative" company and bb2121 and LentiGlobin are essentially curing some patients, but the benefits "are not without serious risks." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/12/18
BOFA
12/12/18
NO CHANGE
Target $190
BOFA
Buy
Facebook testing search ads may unlock new revenue stream, says BofA/Merrill
BofA/Merrill analyst Justin Post kept his Buy rating and $190 price target on Facebook (FB), saying there is potential for "high value search activity" on its platform if its testing of search ads within the Marketplace section - as reported by TechCrunch - bears fruit. The analyst notes that the report anticipates the search ad testing to be rolled out with a small set of auto and e-commerce advertisers, modeling that the company could generate up to $5B in annual search related ad revenue under the assumption of offering a 75% discount to Google's (GOOGL) revenue per search. Post maintains his positive view on Facebook and its monetization opportunities.
12/10/18
DBAB
12/10/18
NO CHANGE
DBAB
Buy
Facebook valuation 'extremely attractive' at current levels, says Deutsche Bank
Facebook remains the best risk/reward in large cap internet given the potential for core engagement to stabilize, for monetization in the Stories format to drive a potential re-acceleration in growth in mid-2019, for the negative news cycle to abate and given the "extremely attractive" current valuation, Deutsche Bank analyst Lloyd Walmsley tells investors in a research note. The analyst is encouraged that on top of Facebook's "relatively aggressive" share buyback to-date, the board expanded the repurchase authorization again by an additional $9B. He reiterates a Buy rating on Facebook shares.
12/06/18
12/06/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. LG Display (LPL) initiated with a Buy at Citi. 2. Twitter (TWTR) and Alphabet (GOOG, GOOGL) were initiated with a Buy at Guggenheim, while Snap (SNAP) and Facebook (FB) were initiated with a Neutral. 3. Apache (APA) initiated with an Overweight at Stephens. 4. CorMedix (CRMD) initiated with a Buy at Roth Capital. 5. Protagonist Therapeutics (PTGX) initiated with a Buy at Nomura Instinet. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
GIS General Mills
$36.70

-0.03 (-0.08%)

09/17/18
09/17/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. LULULEMON UPGRADED TO OUTPERFORM: Wells Fargo analyst Ike Boruchow upgraded Lululemon (LULU) to Outperform from Market Perform, stating that while the brand's current strength is "evident to essentially everyone," his recent meetings with management lead him to believe that its "industry leading" momentum is likely sustainable through the second half of this year and well into 2019. While admitting to being "late to the party," Boruchow said he sees meaningful outperformance and upward revisions being ahead for the athletic apparel company. He raised his price target on Lululemon shares to $200 from $144. In late morning trading, Lululemon shares are higher by 2.3%. NOMURA UPGRADES BROADCOM TO BUY: Nomura Instinet analyst Romit Shah upgraded Broadcom (AVGO) to Buy from Neutral and raised his price target for the shares to $300 from $225. The analyst says the "so many positive takeaways from earnings" have forced him to take a more constructive stance on the shares. GOLDMAN SWAPS CONVICTION BUY ON MASTERCARD, VISA: Goldman Sachs analyst James Schneider added MasterCard (MA) to his firm's Conviction List while maintaining a Buy rating on the shares. The analyst also upped his price target for the stock to $260 from $230. Goldman Sachs analyst James Schneider removed Visa (V) from his firm's Conviction List but maintains a Buy rating on the shares with an unchanged price target of $160. The analyst, who continues to see upside to Street estimates, cites the recent share outperformance for the removal. MORGAN STANLEY INITIATES CONSUMER STAPLES: Morgan Stanley analyst Dara Mohsenian assumed Kraft Heinz (KHC) with an Underweight and $52 price target, as he believes it topline growth will likely trail food peers. In late morning trading, Kraft Heinz shares were down almost 2%. The analyst also assumed coverage of Mondelez (MDLZ), General Mills (GIS), and Kellogg (K) with Equal Weight ratings. KEYBANC SEES CANNABIS AS DRIVER FOR SHOPIFY: KeyBanc analyst Monika Garb said she is a buyer of Shopify (SHOP), as the company has "ample" growth opportunities ahead, and she sees potential upside to her above-consensus estimates. She expects that recreational sales of cannabis in Canada could be a GMV and revenue driver and further benefit Shopify's business momentum. Garb maintained an Overweight rating and $182 price target on the shares.
12/18/18
JEFF
12/18/18
NO CHANGE
Target $55
JEFF
Buy
General Mills Q2 results, guidance to be better than feared, says Jefferies
The underperformance of General Mills shares reflects the expectation of a guide-down driven by weak Q2 Pet results, Jefferies analyst Akshay Jagdale tells investors in a research note. The analyst, however, believes the company's fiscal 2019 guidance already contemplates weak Q2 Pet results and that an acceleration in Pet earnings in the second half of the year is achievable. Further, General Mills' base business sales growth trends have improved in Q2 and its earnings growth guidance is conservative, says Jagdale. As such, he expects the company's Q2 results and guidance will be better than feared. The analyst keeps a Buy rating on General Mills with a $55 price target.
11/14/18
JPMS
11/14/18
DOWNGRADE
Target $66
JPMS
Neutral
JPMorgan downgrades Kellogg to Neutral, removes from Analyst Focus List
JPMorgan analyst Ken Goldman downgraded Kellogg (K) to Neutral from Overweight and lowered his price target for the shares to $66 from $73. The analyst also removed the stock from his firm's Analyst Focus List. He says that while nothing at the company's investor day "necessarily disappointed" him, he also did not gain "much comfort that the bottom-line turnaround would be swift." Maintaining an Overweight rating in the face of flat EBIT growth in both 2018 and 2019 "requires a bit more patience than we have at the moment," Goldman writes in a note to investors. With that said, the analyst did raise the likelihood that Kellogg gets taken out at a 25% premium to 15% from 5% in his scenario analysis. This is not because of anything specific to Kellogg, but rather because Kraft Heinz (KHC) seems close to buying something in consumer staples, says the analyst. Goldman sees a number of companies are potential targets, including General Mills (GIS), Kellogg, an overseas food producer, or a consumer staples company outside food.
12/14/18
UBSW
12/14/18
NO CHANGE
Target $40
UBSW
Neutral
General Mills price target cut to $40 from $46 at UBS
UBS analyst Steven Strycula maintained a Neutral rating on General Mills but cut his price target to $40, telling investors in a research note that buy-side expectations are low for Q2 results, yet he is modeling sales and EPS below consensus. His primary concern in Q2 is that Street estimates for Blue Buffalo sales remain too high, and is concerned that disappointing pet food sales could push shares to new stock lows.
JBL Jabil
$22.21

0.65 (3.01%)

11/12/18
GSCO
11/12/18
UPGRADE
Target $25
GSCO
Neutral
Goldman upgrades Jabil to Neutral with shares near $25 target
Goldman Sachs analyst Mark Delaney last night upgraded Jabil to Neutral from Sell with an unchanged price target of $25. The analyst cities valuation for the upgrade with the shares near his price target. Jabil's valuation at current share levels better reflects concerns around margin and customer concentration risk, Delaney tells investors in a research note. Further, he believes the company has made "partial progress" at addressing concerns around diversification. In addition, Jabil is demonstrating better sales momentum than expected, partly from progress in important areas of the market like medical and cloud, says Delaney.
12/11/18
WOLF
12/11/18
INITIATION
Target $9
WOLF
Peer Perform
Flex initiated with a Peer Perform at Wolfe Research
Wolfe Research analyst Steven Milunovich started Flex (FLEX) with a Peer Perform rating and $9 price target, stating that although EMS names are moving up the value chain, he does not think "now is the time" for Flex and Jabil (JBL).
12/11/18
WOLF
12/11/18
INITIATION
Target $25
WOLF
Peer Perform
Jabil initiated with a Peer Perform at Wolfe Research
Wolfe Research analyst Steven Milunovich started Jabil (JBL) with a Peer Perform rating and $25 price target, stating that although EMS names are moving up the value chain, he does not think "now is the time" for Jabil and Flex (FLEX).
11/27/18
SBSH
11/27/18
NO CHANGE
Target $24
SBSH
Sell
Jabil price target lowered to $24 from $28 at Citi
Citi analyst Jim Suva lowered his price target for Jabil (JBL) to $24 and keeps a Sell rating on the shares. The analyst adjusted his valuation of the stock to reflect the recent market decline. His Sell thesis is based on revenue and margin pressure from incremental suppliers getting into the iPhone supply chain. Jabil's customer concentration with Apple (AAPL) gives the company limited bargaining power when demand slows down and/or when there is new competition in the supply chain, Suva tells investors in a research note.
LRCX Lam Research
$138.01

2.39 (1.76%)

11/16/18
WELS
11/16/18
NO CHANGE
Target $45
WELS
Outperform
Applied Materials price target lowered to $45 from $60 at Wells Fargo
Wells Fargo analyst Aaron Rakers lowered his price target on Applied Materials shares to $45 from $60 following the company's Q4 report and Q1 guidance, stating that he thinks shares are being pressured by a lack of visibility into WFE spend bottoming. Applied previously, following the July quarter, said that it expected a return to growth in 2Q19-4Q19, but now is unwilling to call 1Q19 a bottom, according to Rakers. Looking at the combined guidance and estimates for Applied, Lam Research (LRCX) and Tokyo Electron, he thinks investors could consider a low-20% sequential decline in NAND-related spend following a 20% quarter-over-quarter decline in 3Q18 spending levels, Rakers added. Still, he remains positive on Applied's long-term positioning and keeps an Outperform rating on the shares.
10/29/18
RILY
10/29/18
DOWNGRADE
RILY
Neutral
B. Riley FBR downgrades three to Neutral on memory spending concerns
B. Riley FBR analyst Craig Ellis downgraded to Neutral from Buy shares of Axcelis Technologies (ACLS), Applied Materials (AMAT) and Lam Research (LRCX). The analyst recommends trimming Semiconductor exposure on increased fears over memory spending. The analyst sees rising concerns that a chip inventory correction is underway, plus he has "some new NAND spending risks." Further, "ample demand crosscurrents and elevated supply chain inventory" could be further exacerbated if U.S. and China trade friction rises, Ellis tells investors in a research note.
10/29/18
RILY
10/29/18
DOWNGRADE
Target $160
RILY
Neutral
Lam Research downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Craig Ellis downgraded Lam Research to Neutral and lowered his price target for the shares to $160 from $225.
10/23/18
STFL
10/23/18
NO CHANGE
Target $146
STFL
Buy
MKS Instruments price target lowered to $146 following Lam report at Stifel
Stifel analyst Patrick Ho adjusting his Q4 and FY19 estimates for MKS Instruments (MKSI) to "line them up" with the trends pointed to by Lam Research (LRCX) in the latter's September quarter earnings report, noting that, as with Lam prior to its report his estimates were "somewhat high." Given his estimate revisions, Ho lowered his price target on MKS Instruments to $146 from $155, but he added that his "thesis on the name has not changed one bit" and he keeps a Buy rating on MKS shares.
SURF Surface Oncology
$7.35

-0.44 (-5.65%)

05/14/18
GSCO
05/14/18
INITIATION
Target $17
GSCO
Neutral
Surface Oncology initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Salveen Richter initiated Surface Oncology with a Neutral and $17 price target. Richter said the key value driver is SRF 231, which prevents the immune system from recognizing and targeting cancer cells, and in Phase 1 in solid tumors and blood cancers. THe analyst said SRF231 could be a best-in-class asset, but looks for preclinical data translation in humans before becoming more constructive on shares.
05/14/18
EVER
05/14/18
INITIATION
Target $26
EVER
Outperform
Surface Oncology initiated with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Surface Oncology with an Outperform and $26 price target telling investors the company is developing a portfolio of programs that target the immuno-suppresive tumor microenvironment which helps to 'hide' cancer cells from attack by the immune system. The analyst said lead CD47 antibody cancer I/O program is very compelling, with the most exciting aspect of Surface being a terrific management team with multiple shots on goal, providing a meaningful backstop on valuation should the lead program stumble.
05/14/18
05/14/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. General Electric (GE) initiated with a Buy at Gabelli. 2. Western Digital (WDC) initiated with an Overweight at JPMorgan. 3. GrafTech (EAF) initiated with an Overweight at JPMorgan and an Outperform at RBC Capital. 4. Surface Oncology (SURF) initiated with an Outperform at Evercore ISI and Cowen as well as a Neutral at Goldman Sachs. 5. BeiGene (BGNE) initiated with an Outperform at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/18/18
BARD
09/18/18
INITIATION
Target $23
BARD
Outperform
Surface Oncology initiated with an Outperform at Baird
Baird analyst Michael Ulz initiated Surface Oncology with an Outperform and $23 price target.
WGO Winnebago
$19.96

-0.73 (-3.53%)

10/01/18
BMOC
10/01/18
NO CHANGE
Target $60
BMOC
Outperform
Winnebago management and channel checks 'positive', says BMO Capital
BMO Capital analyst Gerrick Johnson kept his Outperform rating and $60 price target on Winnebago, saying its management team was confident in the state of its business at its recent meeting with a view that industry headwinds do not impact the company. The analyst adds that his channel checks suggest that performance at the Grand Design and Winnebago's towable business is positive, while dealers also show optimism toward the company's introduction of more-affordable motorized units.
10/18/18
BARD
10/18/18
NO CHANGE
Target $50
BARD
Outperform
Winnebago price target lowered to $50 from $60 at Baird
Baird analyst Craig Kennison lowered his price target on Winnebago to $50 from $60 following its Q3 report. The analyst noted the industry remains on track for a record year, but he believes the market is discounting a decline-and-destock scenario, which he views as plausible. He believes investors should be patient and they will be rewarded. Kennison reiterated his Outperform rating on Winnebago shares.
12/18/18
NRCS
12/18/18
NO CHANGE
NRCS
Towables, Manufactured Housing seeing steep declines, says Northcoast
Northcoast analyst Seth Woolf's RV dealer survey indicates a deterioration of virtually every metric he tracks, and revealed a meaningfully more cautious view of inventory levels, and suggests the promotional environment intensified. Woolf said the November towable sell-out index came in at 46.3 versus 54.7 in October, while the Manufactured Home index declined to 39.1 versus 47.1 in the prior survey. The analyst is growing less confident Buy rated Camping World (CWH) will be able to achieve its guidance and said anyone with a "floorplan and a pulse can get Thor Industries' (THO) best price.
08/17/18
NRCS
08/17/18
NO CHANGE
NRCS
Northcoast says channel checks pointing to weakening RV demand
Northcoast analyst Seth Woolf said he has become incrementally more cautious on the Recreation & Leisure Products group as his channel checks are pointing to weakening retail demand. While he believes "the buy-side is clearly expecting to see weak wholesale numbers in the coming months," Woolf also contends that the magnitude of declines could be a surprise. He maintains a Buy rating on Camping World (CWH) and Neutral ratings on LCI Industries (LCII), Thor Industries (THO) and Winnebago (WGO).
PAYX Paychex
$64.32

-0.63 (-0.97%)

10/04/18
MOFT
10/04/18
INITIATION
Target $79
MOFT
Neutral
Paychex initiated with a Neutral at MoffettNathanson
MoffettNathanson initiated Paychex with a Neutral and $79 price target.
11/14/18
LEHM
11/14/18
INITIATION
Target $69
LEHM
Equal Weight
Paychex initiated with an Equal Weight at Barclays
Barclays analyst Ramsey El-Assal initiated Paychex with an Equal Weight and $69 price target.
11/26/18
JEFF
11/26/18
NO CHANGE
JEFF
Paychex acquisition of Oasis 'strengthens' segment, says Jefferies
Jefferies analyst Samad Samana believes Paychex acquisition of Oasis for $1.2B in cash is a positive for the company. Samana believe the Oasis acquisition strengthens the business segment, as Paychex gains increased scale, can cross-sell time and attendance and its retirement offerings, and it gives Paychex increased coverage/exposure outside of its core PEO markets. The analyst added that there may be a "longer-term revenue opportunity in converting Oasis's customers from their current software to Paychex Flex." Samana maintained a Hold rating and $75 price target on Paychex shares.
11/14/18
LEHM
11/14/18
INITIATION
LEHM
Overweight
Barclays initiates coverage of U.S. payment processors with PayPal as top pick
As noted earlier, Barclays analyst Ramsey El-Assal initiated a group of 20 U.S. companies in the Payments, Processing, and related IT Services sector with Overweight-rated PayPal (PYPL) as his Top Pick. The analyst cites the company's "100% exposure to high-growth digital channels" along with its "clean balance sheet substantial cash position" that bring it a "strategic opportunity. El-Assal is also particularly positive on Overweight-rated WorldPay (WP) based on its strong growth potential from its exposure to "tech-enabled channels" and merger synergies, FirstData (FDC) based on the accelerating growth of its merchant channels, and Square (SQ)," whose Subscription & Services segment is blurring the lines between Payments and software". The analyst contends that the extent of being "tech-enabled" is a key differentiator in the Payments industry, assigning an Overweight rating to Alliance Data Systems (ADS), ADP (ADP), Cardtronics (CATM), Fidelity National (FIS), First Data (FDC), Fiserv (FISV), Fleetcor Technologies (FLT), Global Payments (GPN), Green Dot (GDOT), Mastercard (MA), Total System Services (TSS), Visa (V), and WEX Inc (WEX). El-Assal assigns Equal-weight ratings to EVO Payments (EVOP) and Paychex (PAYX), stating that while the companies are "solid performers" in the space, their valuation is seen as more balanced. The analyst rates MoneyGram (MGI) and Western Union (WU) at Underweight, saying that the former will struggle to re-ignite positive growth as the costs associated with regulatory scrutiny weigh on its profits and the latter will be challenged by "periodic pricing pressure eroding margins over a long period of time."

TODAY'S FREE FLY STORIES

BA

Boeing

$344.09

-25.04 (-6.78%)

08:31
10/19/19
10/19
08:31
10/19/19
08:31
Periodicals
Boeing recovery getting 'a lot more complicated,' Barron's says »

Boeing shares fell on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

GMVHF

GVC Holdings

$0.00

(0.00%)

08:27
10/19/19
10/19
08:27
10/19/19
08:27
Periodicals
GVC Holdings looking like 'a good bet,' Barron's says »

GVC Holdings' stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EYE

National Vision

$22.98

-0.94 (-3.93%)

08:19
10/19/19
10/19
08:19
10/19/19
08:19
Periodicals
Street sees National Vision as a buy, some shorts disagree, Barron's says »

National Vision has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CI

Cigna

$167.11

2.3 (1.40%)

, HUM

Humana

$289.59

4 (1.40%)

08:13
10/19/19
10/19
08:13
10/19/19
08:13
Periodicals
Healthcare stocks getting 'back on their feet,' Barron's says »

The sector is the second…

CI

Cigna

$167.11

2.3 (1.40%)

HUM

Humana

$289.59

4 (1.40%)

UNH

UnitedHealth

$245.59

1.84 (0.75%)

WCG

WellCare

$274.54

0.09 (0.03%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$123.03

1.47 (1.21%)

TEVA

Teva

$7.50

-0.26 (-3.35%)

AZN

AstraZeneca

$43.86

-0.25 (-0.57%)

BMY

Bristol-Myers

$53.02

0.6 (1.14%)

LLY

Eli Lilly

$108.68

0.24 (0.22%)

GSK

GlaxoSmithKline

$42.52

0.04 (0.09%)

JNJ

Johnson & Johnson

$127.73

-8.47 (-6.22%)

MRK

Merck

$84.68

0.88 (1.05%)

NVS

Novartis

$86.86

-0.395 (-0.45%)

PFE

Pfizer

$36.46

(0.00%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$46.13

-0.43 (-0.92%)

ANTM

Anthem

$249.55

0.3 (0.12%)

CVS

CVS Health

$66.17

-0.31 (-0.47%)

CNC

Centene

$46.92

-0.28 (-0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 31

    Oct

  • 31

    Oct

  • 31

    Oct

  • 04

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

  • 08

    Nov

  • 13

    Nov

  • 14

    Nov

  • 18

    Nov

  • 07

    Dec

  • 24

    Jan

  • 24

    Jan

  • 14

    Mar

COP

ConocoPhillips

$53.99

-0.55 (-1.01%)

08:03
10/19/19
10/19
08:03
10/19/19
08:03
Periodicals
ConocoPhillips stock looking cheap following selloff, Barron's says »

At a time when Wall…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 19

    Nov

AMZN

Amazon.com

$1,757.77

-30.07 (-1.68%)

, NFLX

Netflix

$275.40

-17.88 (-6.10%)

08:00
10/19/19
10/19
08:00
10/19/19
08:00
Periodicals
Comcast stacking up better than investors might expect, Barron's says »

If cord-cutting…

AMZN

Amazon.com

$1,757.77

-30.07 (-1.68%)

NFLX

Netflix

$275.40

-17.88 (-6.10%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$45.58

-0.36 (-0.78%)

T

AT&T

$38.46

0.64 (1.69%)

DIS

Disney

$130.91

-1.46 (-1.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 07

    Nov

  • 18

    Nov

  • 19

    Nov

  • 21

    Nov

AKS

AK Steel

$2.45

0.055 (2.30%)

, MT

ArcelorMittal

$14.58

0.03 (0.21%)

07:41
10/19/19
10/19
07:41
10/19/19
07:41
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

AKS

AK Steel

$2.45

0.055 (2.30%)

MT

ArcelorMittal

$14.58

0.03 (0.21%)

NUE

Nucor

$51.69

-0.11 (-0.21%)

STLD

Steel Dynamics

$28.71

-0.04 (-0.14%)

TMST

TimkenSteel

$5.42

-0.015 (-0.28%)

X

U.S. Steel

$10.72

0.1 (0.94%)

GM

General Motors

$36.19

-0.01 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Oct

  • 31

    Oct

  • 01

    Nov

AAVMY

ABN Amro

$0.00

(0.00%)

, BBVA

Banco Bilbao

$5.38

0.07 (1.32%)

04:55
10/19/19
10/19
04:55
10/19/19
04:55
Conference/Events
Institute of International Finance to hold annual meeting »

2019 IIF Annual Meeting…

AAVMY

ABN Amro

$0.00

(0.00%)

BBVA

Banco Bilbao

$5.38

0.07 (1.32%)

BCS

Barclays

$8.48

0.11 (1.31%)

BLK

BlackRock

$445.26

-5.56 (-1.23%)

BNPQY

BNP Paribas

$0.00

(0.00%)

C

Citi

$69.76

0.16 (0.23%)

CAIXY

CaixaBank

$0.00

(0.00%)

CIB

Bancolombia

$49.65

0.12 (0.24%)

CS

Credit Suisse

$12.34

0.045 (0.37%)

EV

Eaton Vance

$44.07

-0.49 (-1.10%)

GS

Goldman Sachs

$206.61

0.13 (0.06%)

HSBC

HSBC

$38.72

-0.165 (-0.42%)

JPM

JPMorgan

$120.60

0.21 (0.17%)

MA

MasterCard

$270.90

-5.74 (-2.07%)

MCO

Moody's

$217.41

-1.33 (-0.61%)

MS

Morgan Stanley

$43.70

0.25 (0.58%)

NYT

New York Times

$29.76

0.21 (0.71%)

PYPL

PayPal

$101.25

-2.38 (-2.30%)

RBS

RBS

$6.14

0.205 (3.46%)

RY

Royal Bank of Canada

$81.49

0.38 (0.47%)

SMFG

Sumitomo Mitsui

$6.87

-0.04 (-0.58%)

SPGI

S&P Global

$250.62

-2.15 (-0.85%)

STT

State Street

$63.40

3.69 (6.18%)

UBS

UBS

$11.35

0.09 (0.80%)

V

Visa

$175.83

-2.11 (-1.19%)

ZURVY

Zurich Insurance

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 27

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 31

    Oct

  • 31

    Oct

  • 04

    Nov

  • 06

    Nov

  • 10

    Nov

  • 12

    Nov

  • 21

    Nov

  • 04

    Dec

  • 10

    Dec

  • 07

    Jan

  • 14

    Jan

  • 14

    Jan

STT

State Street

$63.40

3.69 (6.18%)

20:09
10/18/19
10/18
20:09
10/18/19
20:09
Upgrade
State Street rating change at Keefe Bruyette »

State Street upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

SUN

Sunoco

$32.43

0.32 (1.00%)

19:53
10/18/19
10/18
19:53
10/18/19
19:53
Upgrade
Sunoco rating change at BMO Capital »

Sunoco upgraded to Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLF

Tandy Leather

$4.61

(0.00%)

18:24
10/18/19
10/18
18:24
10/18/19
18:24
Hot Stocks
Tandy Leather CFO Castillo to step down »

Tandy Leather Factory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLF

Tandy Leather

$4.61

(0.00%)

18:23
10/18/19
10/18
18:23
10/18/19
18:23
Hot Stocks
Tandy Leather says most recent annual report statements not reliable »

Tandy Leather Factory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$236.29

0.99 (0.42%)

18:03
10/18/19
10/18
18:03
10/18/19
18:03
Hot Stocks
U.S. lawmakers request Apple restore HKMapp app in Hong Kong »

U.S. Senators Ron Wyden,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

JPM

JPMorgan

$120.60

0.21 (0.17%)

, FB

Facebook

$185.96

-4.435 (-2.33%)

17:59
10/18/19
10/18
17:59
10/18/19
17:59
Periodicals
JPMorgan CEO says Libra 'a neat idea that will never happen,' Reuters says »

JPMorgan (JPM) CEO Jamie…

JPM

JPMorgan

$120.60

0.21 (0.17%)

FB

Facebook

$185.96

-4.435 (-2.33%)

PYPL

PayPal

$101.25

-2.38 (-2.30%)

MA

MasterCard

$270.90

-5.74 (-2.07%)

V

Visa

$175.83

-2.11 (-1.19%)

EBAY

eBay

$38.82

-0.31 (-0.79%)

BKNG

Booking Holdings

$2,012.20

-16.43 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 27

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 04

    Nov

  • 21

    Nov

  • 14

    Jan

GLD

SPDR Gold Shares

$140.47

-0.13 (-0.09%)

17:52
10/18/19
10/18
17:52
10/18/19
17:52
Hot Stocks
SPDR Gold Shares holdings rise to 924.64MT from 918.19MT »

This is the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$16.48

0.11 (0.67%)

17:43
10/18/19
10/18
17:43
10/18/19
17:43
Hot Stocks
Teck Resources gets approval for stock buyback for up to 40M class B shares »

Teck Resources has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

OSK

Oshkosh

$77.22

0.46 (0.60%)

17:41
10/18/19
10/18
17:41
10/18/19
17:41
Hot Stocks
Oshkosh awarded $159.14M Army contract for medium tactical vehicle production »

Oshkosh was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 19

    Nov

  • 20

    Nov

OVLY

Oak Valley Bancorp

$16.40

-0.16 (-0.97%)

17:35
10/18/19
10/18
17:35
10/18/19
17:35
Earnings
Oak Valley Bancorp reports Q3 EPS 40c vs. 37c last year »

Reports Q3 NII $10.4M vs.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTNW

FTE Networks

$0.79

-0.0185 (-2.29%)

17:21
10/18/19
10/18
17:21
10/18/19
17:21
Hot Stocks
FTE Networks receives noncompliance notice from NYSE American »

FTE Networks announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNXP

Tonix Pharmaceuticals

$0.45

0.0048 (1.07%)

17:12
10/18/19
10/18
17:12
10/18/19
17:12
Syndicate
Breaking Syndicate news story on Tonix Pharmaceuticals »

Tonix Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RLMD

Relmada Therapeutics

$20.18

1.07 (5.60%)

17:10
10/18/19
10/18
17:10
10/18/19
17:10
Syndicate
Breaking Syndicate news story on Relmada Therapeutics »

Relmada Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:55
10/18/19
10/18
16:55
10/18/19
16:55
General news
Breaking General news story  »

Dallas Federal Reserve…

NWSA

News Corp.

$13.48

-0.19 (-1.39%)

, NWS

News Corp

$13.79

-0.11 (-0.79%)

16:51
10/18/19
10/18
16:51
10/18/19
16:51
Periodicals
Facebook reaches pact with News Corp., others for news section, WSJ says »

News Corp. (NWSA) has…

NWSA

News Corp.

$13.48

-0.19 (-1.39%)

NWS

News Corp

$13.79

-0.11 (-0.79%)

FB

Facebook

$185.96

-4.435 (-2.33%)

NYT

New York Times

$29.76

0.21 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 23

    Oct

  • 27

    Oct

  • 30

    Oct

  • 06

    Nov

WAIR

Wesco Aircraft

$11.01

0.01 (0.09%)

16:46
10/18/19
10/18
16:46
10/18/19
16:46
Conference/Events
Wesco Aircraft to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

FOMX

Foamix

$3.15

-0.09 (-2.78%)

16:41
10/18/19
10/18
16:41
10/18/19
16:41
Hot Stocks
Breaking Hot Stocks news story on Foamix »

Foamix up 7.5% at $3.35…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 20

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.